Daniel R Briggi, James Reilly, Josiel Garcia, Wyatt Kupperman
{"title":"SCS for CRPS: A Review of Cost-Effectiveness Models.","authors":"Daniel R Briggi, James Reilly, Josiel Garcia, Wyatt Kupperman","doi":"10.1007/s11916-025-01388-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purposeof review: </strong>The provision of a review of current literature on the cost-effectiveness of employing SCS in the treatment of CRPS.</p><p><strong>Recent findings: </strong>Four studies were included in this review, with authorship in the United States, Canada, Europe, and Australia. Each study individually supported the cost-effectiveness of SCS in the treatment of CRPS, with the incremental cost of one quality-adjusted life year found to be AUD 2,321 - USD 22,084, all below a willingness to pay estimated at USD 50,000. One of the four studies was rated American Academy of Neurology (AAN) Grade II, three of the four studies were rated AAN Grade III, and an overall Class C evaluation was assigned to this evidence. SCS can be cost-effective in the treatment of patients with CRPS when considering a time horizon of at least ten years. Current evidence, however, remains weak and less invasive options remain first-line.</p>","PeriodicalId":50602,"journal":{"name":"Current Pain and Headache Reports","volume":"29 1","pages":"75"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pain and Headache Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11916-025-01388-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purposeof review: The provision of a review of current literature on the cost-effectiveness of employing SCS in the treatment of CRPS.
Recent findings: Four studies were included in this review, with authorship in the United States, Canada, Europe, and Australia. Each study individually supported the cost-effectiveness of SCS in the treatment of CRPS, with the incremental cost of one quality-adjusted life year found to be AUD 2,321 - USD 22,084, all below a willingness to pay estimated at USD 50,000. One of the four studies was rated American Academy of Neurology (AAN) Grade II, three of the four studies were rated AAN Grade III, and an overall Class C evaluation was assigned to this evidence. SCS can be cost-effective in the treatment of patients with CRPS when considering a time horizon of at least ten years. Current evidence, however, remains weak and less invasive options remain first-line.
期刊介绍：
This journal aims to review the most important, recently published clinical findings regarding the diagnosis, treatment, and management of pain and headache. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of pain and headache.
We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as anesthetic techniques in pain management, cluster headache, neuropathic pain, and migraine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
